Ralf Pasternack studied Chemistry at the Technical University Darmstadt and received his Diploma in Biochemistry in 1994 working in the group of Prof. H.G. Gassen. In 1998 he obtained his PhD working on Microbial Transglutaminase from Streptomyces together with Prof. H.-L. Fuchsbauer & Prof. H.G. Gassen.
Together with both supervisors and Dr. Jochen Klein (former CEO of the Doehler Group) he founded his first core biotech company called N-Zyme BioTec and served as CEO.
Ralf co-founded Zedira through a management buyout in 2007 and has held the position of CEO ever since.
Connect on LinkedIn
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation